Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Tricks Are Crucial For Industry As OTC Bump Wanes

This article was originally published in The Tan Sheet

Executive Summary

OTC firms must embrace new marketing strategies more readily to overcome the ebb in recession-driven industry growth, according to industry stakeholders.

You may also be interested in...



Friends Rival TV As Top Influence For Purchases

Social media is well-suited to OTC drug marketing, but the industry has been slow to enter that world, says public relations executive Robin Russo.

Friends Rival TV As Top Influence For Purchases

Social media is well-suited to OTC drug marketing, but the industry has been slow to enter that world, says public relations executive Robin Russo.

Friends Rival TV As Top Influence For Purchases

Social media is well-suited to OTC drug marketing, but the industry has been slow to enter that world, says public relations executive Robin Russo.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105008

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel